Details of the Drug Reposition

General Information of This Drug (ID: DMTBAV3)

Drug Name
RX-0201   DMTBAV3
Therapeutic Class
Anticancer Agents

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [1]
Pancreatic cancer DISJC981 2C10 Phase 2 [2]
Renal cell carcinoma DISQZ2X8 2C90 Phase 2 [3]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01028495) A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)